This is a competitive renewal application for the Cancer Center Support Grant of Roswell Park Cancer Institute (RPCI). an NCI-designated Comprehensive Cancer Center, for the grant period 1985 - 2000. Under the leadership of Institute President and CEO, Thomas B. Tomasi, M.D., Ph.D, this grant is entering its 20th year of uninterrupted funding. Over the past two decades, the CCSG has provided indispensable support to the research programs of RPCI. The present CCSG application reflects the significant evolution and progress of RPCIs research programs with the inclusion of 6 mature programs, 2 developing programs and 12 shared resources, seven of which are new or significantly expanded resources carried over from the merger of the Institute Core Grant with the Grace Cancer Drug Center Core Grant. Since the last CCSG renewal, there have been numerous changes in the RPCI research programs including recruitment of new senior faculty, scientific and clinical departments have been reorganized, major capital investments and the commitment of New York State to design and build a new research laboratory, vivarium, nursing tower, ambulatory clinic and diagnostic and treatment facility, all in addition to major renovations to existing research facilities. The CCSG plays a central role in the planning and evaluation, support and administration of Roswell's basic and clinical research programs. With the renewal of this CCSG, combined with the commitment of New York State to support the cancer mission of Roswell Park and its highly dedicated research faculty, Roswell Park will be poised to enter the next century as one of the nations leading cancer centers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-22
Application #
2414072
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1983-12-01
Project End
2000-04-30
Budget Start
1997-06-16
Budget End
1998-04-30
Support Year
22
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Barger, Carter J; Zhang, Wa; Sharma, Ashok et al. (2018) Expression of the POTE gene family in human ovarian cancer. Sci Rep 8:17136
Chen, George L; Carpenter, Paul A; Broady, Raewyn et al. (2018) Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 24:373-380
Eng, Kevin H; Szender, J Brian; Etter, John Lewis et al. (2018) Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genet 14:e1007194
Tubbs, Anthony; Sridharan, Sriram; van Wietmarschen, Niek et al. (2018) Dual Roles of Poly(dA:dT) Tracts in Replication Initiation and Fork Collapse. Cell 174:1127-1142.e19
Bucsek, Mark J; Giridharan, Thejaswini; MacDonald, Cameron R et al. (2018) An overview of the role of sympathetic regulation of immune responses in infectious disease and autoimmunity. Int J Hyperthermia 34:135-143
Leonova, Katerina; Safina, Alfiya; Nesher, Elimelech et al. (2018) TRAIN (Transcription of Repeats Activates INterferon) in response to chromatin destabilization induced by small molecules in mammalian cells. Elife 7:
Verma, Aparajita; Rich, Laurie J; Vincent-Chong, Vui King et al. (2018) Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer. J Oral Pathol Med 47:484-491
Sheffer, Christine E; Miller, Austin; Bickel, Warren K et al. (2018) The treasure of now and an uncertain future: Delay discounting and health behaviors among cancer survivors. Cancer 124:4711-4719
Nesher, Elimelech; Safina, Alfiya; Aljahdali, Ieman et al. (2018) Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. Cancer Res 78:1431-1443
Azad, T; Janse van Rensburg, H J; Lightbody, E D et al. (2018) A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis. Nat Commun 9:1061

Showing the most recent 10 out of 1555 publications